McKesson Corporation (MCK) Q2 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary indicates strong financial performance with raised guidance, robust revenue and operating profit growth, strategic acquisitions, and shareholder returns through share repurchases and dividend hikes. The Q&A section highlights positive analyst sentiment, with strong specialty volume trends and effective margin management. Despite some nonrecurring gains and vague responses, the overall sentiment remains positive. The raised guidance and strategic initiatives suggest a likely stock price increase, making a positive rating appropriate.
Key Financial Performance
Consolidated Revenues Increased 10% year-over-year to $103 billion. This growth reflects robust performance across the portfolio of businesses, particularly in the North American Pharmaceutical segment and the Oncology and Multispecialty segment.
Adjusted Earnings Per Diluted Share Increased 39% year-over-year to $9.86. This increase was driven by robust core operational performance, contributions from acquisitions, net gains from the sale of an equity investment, and a lower effective tax rate.
Gross Profit Increased 9% year-over-year to $3.5 billion. This was primarily due to strong specialty distribution and provider growth within the Oncology and Multispecialty segment.
Operating Expenses Decreased 1% year-over-year to $2 billion. This decrease reflects divestitures in the Canadian business and disciplined cost optimization initiatives in the Medical-Surgical Solutions segment, partially offset by investments in the Oncology and Multispecialty segment.
Operating Profit Increased 26% year-over-year to $1.6 billion. This growth was driven by increased specialty distribution volumes, demand for access solutions, and cost optimization initiatives.
Free Cash Flow $2.2 billion in the second quarter, reflecting disciplined working capital management and strong operating execution.
North American Pharmaceutical Segment Revenue Increased 8% year-over-year to $86.5 billion. This growth was driven by higher prescription volumes from retail national account customers and specialty products.
Oncology and Multispecialty Segment Revenue Increased 32% year-over-year to $12 billion. This growth was driven by strong provider and specialty distribution growth, including contributions from acquisitions.
Oncology and Multispecialty Segment Operating Profit Increased 71% year-over-year to $397 million. This growth was driven by increased provider and specialty distribution volumes and contributions from acquisitions.
Prescription Technology Solutions Segment Revenue Increased 9% year-over-year to $1.4 billion. This growth was driven by increased prescription volumes across third-party logistics and technology services businesses.
Prescription Technology Solutions Segment Operating Profit Increased 20% year-over-year to $261 million. This growth was driven by increased demand for access solutions, including prior authorization services for GLP-1 medications.
Medical-Surgical Solutions Segment Revenue Flat year-over-year at $2.9 billion. Higher volumes of Specialty Pharmaceuticals were offset by lower contributions from illness season products and testing.
Medical-Surgical Solutions Segment Operating Profit Increased 2% year-over-year to $249 million. This growth was driven by operational efficiencies from cost optimization initiatives, partially offset by lower contributions from illness season products and testing.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
InspiroCare launch: Introduced a patient hub to simplify the journey of cell and gene therapies, providing personalized support for patients.
Cold chain facility: Opened a 12,000-foot facility for cell and gene therapy distribution with advanced storage technology.
Oncology and multispecialty segment: Focused on accelerating strategy in higher growth, higher-margin segments, serving over 14,000 providers.
PRISM Vision expansion: Expanded footprint with Spokane Eye Clinic, marking a milestone in building a national eye care platform.
Automation investments: Implemented advanced technologies like order storage retrieval systems, reducing human touches in processes and enhancing efficiency.
Drug Supply Chain Security Act compliance: Achieved serialized transaction data exchange with supply chain participants, enhancing safety and transparency.
Medical-Surgical business separation: Targeting an IPO and subsequent spin-off or split-off by the second half of 2027.
New reporting structure: Introduced to enhance transparency and align with growth areas, including oncology and biopharma services.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Compliance: The company is actively working to comply with the Drug Supply Chain Security Act, which involves complex implementation processes. Any misstep could lead to regulatory penalties or disruptions in operations.
Supply Chain Complexity: Investments in automation and advanced technologies are being made to handle the growing complexity of supply chain management. However, any failure in these systems could disrupt operations and customer service.
Market Conditions for Medical-Surgical Business: The planned separation of the Medical-Surgical business is subject to market conditions and regulatory approvals, which could delay or complicate the process.
Illness Season Variability: Lower-than-expected illness season product demand, including vaccines and testing, has already impacted revenues in the Medical-Surgical segment. This variability could continue to affect financial performance.
Acquisition Integration: The integration of recent acquisitions like PRISM Vision and Core Ventures is critical for achieving projected growth. Any delays or inefficiencies in integration could impact financial outcomes.
Dependence on Specialty Products: A significant portion of revenue growth is tied to specialty products, including GLP-1 medications. Any changes in market demand, payer requirements, or supply shortages could adversely affect performance.
Economic and Policy Environment: The company operates in a dynamic market and policy backdrop, which could introduce uncertainties affecting strategic execution and financial performance.
Technology Investments: Significant investments in technology and automation are being made to modernize operations. Any delays or failures in these initiatives could hinder operational efficiency and growth.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Adjusted Earnings Per Share (EPS) Guidance: McKesson raised its guidance for adjusted earnings per diluted share to a range of $38.35 to $38.85 for fiscal 2026, reflecting 16% to 18% growth over the prior year.
Revenue Growth: The company anticipates revenue growth of 11% to 15% for fiscal 2026, driven by growth across all core businesses.
Operating Profit Growth: Operating profit is expected to grow by 12% to 16%, supported by continued momentum and execution.
North American Pharmaceutical Segment: Revenue is expected to increase by 10% to 14%, with operating profit growth of 5% to 9%, driven by solid utilization trends, volume growth, and specialty distribution expansion.
Oncology and Multispecialty Segment: Revenue growth is projected at 27% to 31%, with operating profit growth of 49% to 53%, supported by acquisitions and strong organic specialty distribution volume growth.
Prescription Technology Solutions Segment: Revenue is expected to grow by 9% to 13%, with operating profit growth of 13% to 17%, driven by strong organic volume growth and momentum across access and affordability solutions.
Medical-Surgical Solutions Segment: Revenue and operating profit are anticipated at the low end of 2% to 6% growth due to lower-than-expected illness season product volumes and lower volumes across ambulatory and extended care settings.
Free Cash Flow: McKesson expects free cash flow of approximately $4.4 billion to $4.8 billion for fiscal 2026.
Capital Deployment: The company plans to repurchase approximately $2.5 billion of shares in fiscal 2026.
Medical-Surgical Business Separation: McKesson plans to separate its Medical-Surgical Solutions business through an initial public offering, followed by a spin-off or split-off transaction, targeting completion by the second half of calendar 2027, subject to market conditions and regulatory approvals.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Dividend Payments: During the quarter, McKesson returned $89 million in dividend payments to shareholders.
Share Repurchases: McKesson repurchased $818 million worth of shares during the quarter as part of its capital deployment strategy.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What is driving the margin profile in North America Pharmaceutical and Prescription Technology Solutions?
A:The margin profile is driven by a mix of factors, including growth in technology services components, new products, enhanced programs, and access programs like prior authorizations for GLP-1. Investments are expected to increase in the second half of the year, but strong operating profit growth is anticipated to continue.
Q:Was the beat in oncology and multispecialty results already included in the guidance?
A:Most of the nonrecurring gains were included in the guidance at Investor Day, except for one item that was more back-half weighted. Organic business growth is at 13% year-over-year, in line with long-term guidance, and acquisitions are performing well.
Q:Can you elaborate on the health system strength in the quarter?
A:The health system business has shown strong performance due to market-leading share and strong traffic flow through customer settings. This segment has been a focus area for the company.
Q:How should we think about the tax rate for the year?
A:The tax rate varies quarter-to-quarter due to income mix and timing of discretes. The second half is expected to have a slightly higher rate, with Q3 at 23%-25% and a lower rate in Q4. Full-year guidance is 18%-19%.
Q:Do you expect specialty volume trends to continue in the second half of the year?
A:Specialty volume trends have been strong in the first half, driven by good patient flow and the ability to treat more complicated oncology patients. The company continues to expand its network and sees strength in this segment.
Q:What does a market decision within the U.S. oncology network mean?
A:Market decisions involve entering or exiting markets based on alignment with U.S. oncology strategies. In the quarter, the company exited two markets and realized an equity investment gain. These are nonrecurring events.
Q:Why is the Pharma segment growth expected to slow in the second half of the year?
A:The slowdown is due to the onboarding of a new strategic customer in the prior year and the exit of Canada-based businesses, which impacted first-half results. These factors are not present in the second half.
Q:How will an increase in uninsured individuals paying cash for prescriptions impact the RxTS business?
A:The impact is expected to be minimal as the population eligible for discounted prices remains small. The company has tools to support affordability and is engaged with policymakers to advance healthcare solutions.
Q:What is driving the trend of SG&A being down while gross profit accelerates?
A:The trend is driven by the exit of Canada-based businesses, a favorable business mix, and efficiency improvements through technology and AI. Investments in prior years are yielding results.
Q:Are the gains from U.S. oncology network rationalization one-off events?
A:Yes, these gains are nonrecurring and include market exits and the realization of an equity investment gain. They are not included in normal profit streams.
Q:How is the PRISM platform progressing?
A:The PRISM platform is progressing well, with new additions like Spokane. The company is focused on building out the Vision platform and is pleased with the integration and progress.
Q:What is the economic impact of the $51 million gain in the quarter?
A:The $51 million gain includes both market decisions and the realization of an equity investment. These are nonrecurring items.
Q:Does the Drug Supply Chain Security Act have any operating impact?
A:The Act required significant investment but has been implemented smoothly. It adds value to the company's services and creates barriers for new entrants, though it is not expected to materially impact operations.
Q:What are the mega trends in the RxTS business?
A:The company is focused on streamlining manual processes, leveraging networks and technology, and addressing healthcare problems. It is exploring opportunities for platform expansion both organically and inorganically.
Q:How are the two acquisitions (Florida Cancer Specialist and PRISM) performing relative to guidance?
A:Both acquisitions are performing in line with guidance, with PRISM slightly ahead. The company expects continued expansion and additional synergies over time.
Q:Review of Unclear Management Responses
A:Management avoided giving a direct answer to the question about specialty volume trends, as they did not specify the data set or statistics referenced in the question. Additionally, the response to the question about the impact of uninsured individuals paying cash for prescriptions was vague, with no specific data or detailed analysis provided.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Eye Clinic
Investor Day
North America
Spokane Eye
approach
cell gene
collaboration
community provider
compliance
connectivity
eye care
facility
gene therapy
group
health care
hub
implementation
integrity
level accuracy
milestone
multispecialty segment
offering
oncology multispecialty
organization
people
pillar oncology
reporting structure
requirement
result momentum
service level
storage
touch
transparency
trial
unlock
world class
MCK Transcript
McKesson Corporation (MCK) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Neutral5-12
McKesson Corporation (MCK) Q4 2026 Earnings Call Transcript
Positive5-7
Despite the absence of detailed operational updates, strategic initiatives, and return plans, the financial performance was strong, with significant growth in revenue, operating profit, and EPS. The raised EPS guidance further supports a positive outlook. The lack of negative sentiment in the Q&A indicates no major concerns. These factors suggest a positive stock price movement.
McKesson Corporation (MCK) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Neutral3-11
McKesson Corporation (MCK) Presents at Leerink Global Healthcare Conference 2026 Transcript
Neutral3-11
MCK Slides
MCK Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
